Why ADMA Biologics Inc. (ADMA) Performed Worst On Monday?

We recently published a list of 10 Firms Mirror Wall Street Bloodbath. In this article, we are going to take a look at where ADMA Biologics Inc. (NASDAQ:ADMA) stands against other best worst-performing companies on Monday

Wall Street kicked off the trading week on a sour note anew as investors continued to digest the impact of President Donald Trump’s tariff policies and his criticism of the Federal Reserve.

The tech-heavy Nasdaq fell the most among the major indices, down 2.55 percent, followed by the Dow Jones at 2.48 percent, and the S&P 500 at 2.36 percent.

Ten companies mirrored the market bloodbath, booking significant losses during the day. In this article, we have listed the 10 worst-performing companies on Monday and detailed the reasons behind their declines.

To come up with the list, we considered only the stocks with a $2 billion market capitalization and $5 million in trading volume.

An independent distributor in their pharmacy with a range of biopharmaceutical products on display.

ADMA Biologics Inc. (NASDAQ:ADMA)

ADMA Biologics saw its share price decrease by 7.84 percent on Monday to close at $19.64 apiece as investors sold off amid an overall market pessimism and the lack of fresh catalysts to boost investing appetite.

Last week, ADMA saw a rally in its shares following announcements that it sees minimal to no impact from the ongoing trade tensions globally.

In a news release, ADMA President and CEO Adam Grossman underscored the company being a fully US-based firm, with manufacturing operations, market sales, and customer engagements conducted exclusively within the US.

“The tariffs that have been implemented on foreign goods, services, and manufacturing should have no impact on ADMA and its supply chain or production operations,” he said.

“Our strategic infrastructure not only ensures enhanced supply chain robustness, resilience, and regulatory compliance but also aligns with increasing federal and private sector preferences for US-made products and services,” he added.

ADMA is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics for treating immunodeficient patients at risk for infection and others at risk for certain infectious diseases.

Overall, ADMA ranks 7th on our list of worst-performing companies on Monday. While we acknowledge the potential of ADMA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ADMA but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.